Acute Asthma - Part 1: The First Hour

Recognising severity, treating aggressively, and changing the trajectory before the crash

Acute asthma in the emergency department is not simply a problem of airflow—it is a problem of time, trajectory, and therapeutic intensity.

Every exacerbation follows a trajectory.
Your role is to alter that course early.
What is reversible can become irreversible.

Patients do well when we:

• Recognise severity early

• Deliver adequate-dose bronchodilation immediately

• Initiate systemic anti-inflammatory therapy without delay

They deteriorate when we:

• Underestimate severity

• Undertreat early bronchospasm

• Focus on oxygenation instead of ventilation

The first hour is not about observation—it is about decisive intervention.

---

Framing the Acute Attack: Pathophysiology That Drives Decisions

An acute asthma exacerbation represents acute-on-chronic airway inflammation with superimposed broncho-constriction.

Three processes act simultaneously:

• Airway smooth muscle constriction

• Mucosal edema

• Mucus plugging

These lead to:

• Increased airway resistance

• Prolonged expiration

• Dynamic hyperinflation

• Ventilation–perfusion mismatch

• Progressive hypercapnia

This physiological cascade—particularly air trapping and auto-PEEP—is central to deterioration in severe asthma (Mein & Ferrera, 2025).

Asthma is fundamentally a disease of impaired expiration, not inspiration.

---

Severity Assessment: Why Clinical Impression Fails

Classic signs of severe asthma include:

• Tachypnea ≥30/min

• Tachycardia ≥120/min

• Inability to speak full sentences

• Accessory muscle use

• Diaphoresis

• Pulsus paradoxus

However:

Up to 50% of patients with severe airflow obstruction lack classic signs (Cahill et al., 2025).

This makes objective assessment essential.

---

Objective assessment

Peak Expiratory Flow (PEF)

• <50% predicted → severe

• <25% or <150 L/min → risk of hypercapnia

PEF is a critical tool for:

• Detecting occult severity

• Monitoring response

• Risk stratification (Cahill et al., 2025)

---

Oxygenation

• Pulse oximetry for all patients

• SpO₂ <90% → life-threatening exacerbation

Marked hypoxemia should prompt evaluation for complications (Cahill et al., 2025).

---

⚠️ Critical physiological warning

Even a normal PaCO₂ in acute asthma indicates impending respiratory failure, reflecting reduced alveolar ventilation (Cahill et al., 2025).

---

The First 5–10 Minutes: High-Stakes Decisions

Early ED management should rapidly determine:

1. Severity

2. Response to initial therapy

3. Need for escalation or ventilatory support

Simultaneously, clinicians must consider alternative or coexisting diagnoses such as pneumothorax, pulmonary embolism, or anaphylaxis (Mein & Ferrera, 2025; Cahill et al., 2025).

---

💨 Core ED Management: Evidence-Based Therapy

Modern management converges on three interventions:

Oxygen + bronchodilators + systemic corticosteroids

This approach is consistent across GINA, UpToDate, EMCrit, EM Cases, and CorePendium (GINA, 2025; Cahill et al., 2025; Farkas, 2024; McFarlin et al., 2026).

1. Oxygen: Precision, Not Excess

Target:

• SpO₂ 92–95% (most adults)

• ≥95% in pregnancy

• 88–92% in asthma–COPD overlap

Excess oxygen may worsen hypercapnia and V/Q mismatch, particularly in overlap syndromes (McFarlin et al., 2026).

Pulse oximetry may overestimate saturation in certain populations, necessitating clinical correlation (Cahill et al., 2025).

2. Short-Acting Beta₂-Agonists (SABA)

Mechanism:

Broncho-dilation via β₂-receptor stimulation

Dosing:

Nebulised:

• Albuterol 2.5–5 mg every 20 minutes × 3

MDI with spacer:

• 4–8 puffs every 20 minutes × 3

Severe cases:

• Continuous nebulisation 10–15 mg/hour (McFarlin et al., 2026)

Delivery method:

MDI with spacer provides equivalent efficacy to nebulisation with lower aerosolisation risk (Cahill et al., 2025).

Adverse effects:

• Tachycardia

• Tremor

• Hypokalemia

• Lactic acidosis

These effects are expected and should not limit adequate dosing.

Paradigm shift:

SABA-only therapy is associated with worse outcomes and is no longer recommended (GINA, 2025).

3. Anticholinergics (Ipratropium)

Dosing:

• 500 mcg nebulised every 20 minutes × 3 doses

Benefit:

• Improved lung function

• Reduced hospital admission in moderate–severe exacerbations (McFarlin et al., 2026)

Clinical nuance:

Benefit is limited to early management and not required after stabilization.

4. Systemic Corticosteroids

Role:

Reduce airway inflammation and prevent relapse

Indications:

• Moderate–severe exacerbations

• Incomplete response to bronchodilators

Timing:

• Within the first hour (Cahill et al., 2025)

Systemic corticosteroids are one of the few interventions that truly modify the trajectory of an asthma exacerbation when given early. Importantly, evidence consistently shows that oral steroids are as effective as intravenous therapy in most patients, with no meaningful difference in lung function, admission rates, or length of stay—making the oral route the preferred, simpler, and more cost-effective option when feasible.

Among agents, dexamethasone, prednisolone/prednisone, and methylprednisolone offer comparable clinical outcomes; however, dexamethasone stands out for its shorter course, better tolerability, and improved compliance, while prednisolone remains widely used due to familiarity and cost.

In practice, the choice of drug and route matters far less than ensuring early administration of an adequate dose, as timely steroid therapy is what prevents progression from reversible airway inflammation to fixed, refractory disease.

Dosing:

• Prednisone 40–60 mg PO daily for 5–7 days

• Methylprednisolone 60–125 mg IV (McFarlin et al., 2026)

Evidence insights:

• Early steroids reduce hospitalisation and relapse (Cahill et al., 2025)

• High-dose regimens offer no additional benefit and increase adverse effects (Mein & Ferrera, 2025)

Emerging alternative:

Dexamethasone

• 12–16 mg PO/IV once ± repeat dose

Offers:

• Comparable efficacy

• Improved adherence (McFarlin et al., 2026)

🔥 Common Early Pitfalls

• Delayed steroid administration

• Inadequate bronchodilator dosing

• Reliance on auscultation alone

• Failure to use PEF

• Uncontrolled oxygen delivery

• Discharge on SABA-only therapy

Clinical Synthesis

Acute asthma management is about trajectory modification.

Early recognition + aggressive treatment
= prevention of respiratory failure

Part 1 Take-home

The first hour determines the next 24 hours.

---

📌 Coming in Part 2:

• Refractory asthma

• Magnesium, NIV, rescue therapies

• The crashing asthmatic

• Ventilator strategy

• Discharge & relapse prevention

---

📚 References (AMA Style)

1. Mein SA, Ferrera MC. Management of asthma and COPD exacerbations in adults in the ICU. Chest Crit Care. 2025;3(1):100107.

2. Cahill KN, Dixon AE, Zachrison KS. Acute exacerbations of asthma in adults: Emergency department and inpatient management. UpToDate. Updated September 2025.

3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025 update.

4. McFarlin A, Chan C, Winters M, et al. Asthma in adults. EM:RAP CorePendium. Updated February 2026.

5. Farkas J. Asthma. EMCrit Project. January 2024.

6. Helman A, Sommer L, Mal S. The crashing asthmatic: Recognition and management of life-threatening asthma. Emergency Medicine Cases. April 2024.

7. Morris MJ, Mosenifar Z. Asthma guidelines: Guidelines summary. Medscape. Updated March 2026.